Navigation Links
New compound protects against liver cancer

Scientists have identified a new compound called CDDO-Im that protects against the development of liver cancer in laboratory animals. Experiments, led by researchers at the Johns Hopkins Bloomberg School of Public Health, show CDDO-Im to be effective at doses 100 times lower than other compounds known to prevent cancer in people. Because of its makeup, the researchers believe CDDO-Im could be particularly effective in preventing cancers with a strong link to inflammation, such as liver, colon, prostate and gastric cancers. It could also play a role in preventing diseases such as neurodegeneration, asthma and emphysema. The findings are featured in the February 15, 2006, issue of the journal Cancer Research.

CDDO-Im is a synthetic compound that belongs to a class of cancer-fighting compounds called triterpenoids under development by Dr. Michael Sporn and other study co-authors at Dartmouth Medical School. It is derived from oleanolic acid, a naturally occurring substance found in many plants. Other oleanolic derivatives are known to reduce tumor growth in animals and humans.

Researchers believe CDDO-Im works by activating Nrf2, a master switch known to direct certain enzymes to stimulate the cell's defense mechanisms and remove harmful chemicals from cells. "Activation of the Nrf2 pathway with CDDO-Im could provide protection against a number of diseases triggered by environmental agents," said Thomas Kensler, PhD, a professor with the Bloomberg School's Department of Environmental Health Sciences and lead author of the study.

In their research, Kensler and his colleagues treated laboratory rats with varying doses of CDDO-Im. Two days after treatment with CDDO-Im, the rats were given aflatoxin, a naturally occurring cancer-causing toxin. CDDO-Im treatment led to an 85 percent reduction in pre-cancerous lesions at the lowest dose of 50 micrograms per rat and a 99 percent reduction at the highest dose of 5 milligrams.

Like other compounds derived from oleanolic acid, CDDO-Im also has strong anti-inflammatory properties, which the researchers say makes it ideally suited to the prevention of certain cancers. "When cells become inflamed, they can produce reactive molecules, called free radicals, that can damage DNA and promote cancer development," explained Kensler. "CDDO-Im can also inhibit cancer formation by interfering with this inflammatory process."

Because it can stimulate the body's defense mechanisms at such low doses, Kensler believes that CDDO-Im is an excellent candidate for cancer prevention in humans. "If this compound can produce such a potent and dramatic reduction in the number of pre-cancerous growths, it should have an equally dramatic impact on the development of actual cancers. This study suggests that we may be on the right track in terms of chemoprevention. It may open the door for a new class of compounds that could prevent a number of diseases," said Kensler.


Source:Johns Hopkins University Bloomberg School of Public Health

Related biology news :

1. Researchers discover chemical compounds that affect plant growth
2. Bacterial genome sheds light on synthesizing cancer-fighting compounds
3. Scientists discover the bodys marijuana-like compounds are crucial for stress-induced pain relief
4. Evolution of taste receptor may have shaped human sensitivity to toxic compounds
5. Novel compounds show promise as safer, more potent insecticides
6. Metal-containing compounds show promise as HIV weapon
7. Natural compound from pond scum shows potential activity against Alzheimers
8. Chemical compound inhibits tumor growth, size in new mouse study
9. Seaweed yields new compounds with pharmaceutical potential
10. Phenolic compounds may explain Mediterranean diet benefits
11. UC Berkeley researchers create a biologically-inspired artificial compound eye
Post Your Comments:

(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology: